NSABP Foundation Inc — CureCurrent

How to interpret these research links

Connected source records

The exact organization name NSABP Foundation Inc appears in 60 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials60

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast CancerNCT03628066 · lead sponsor · 2018-10-22

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingNCT03412643 · lead sponsor · 2018-05-14

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboNCT03281954 · lead sponsor · 2017-12-19

ACTIVE_NOT_RECRUITING

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast CancerNCT02296801 · lead sponsor · 2015-01-01

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerNCT02236000 · lead sponsor · 2014-08-01

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and SurgeryNCT01872975 · lead sponsor · 2013-08-01

ACTIVE_NOT_RECRUITING

NSABP Biospecimen Discovery ProjectNCT01850628 · lead sponsor · 2013-07-01

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast CancerNCT01705691 · lead sponsor · 2012-09-01

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerNCT01547741 · lead sponsor · 2012-04-01

Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 TrialNCT01424865 · lead sponsor · 2011-11-01

Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28NCT01420185 · lead sponsor · 2011-10-01

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast CancerNCT01399359 · lead sponsor · 2011-08-01

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32NCT01286233 · lead sponsor · 2011-07-01

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast CancerNCT01423123 · lead sponsor · 2011-05-01

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast CancerNCT01008150 · lead sponsor · 2010-10-01

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerNCT00887536 · lead sponsor · 2009-05-01

Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2NCT00967239 · lead sponsor · 2009-04-01

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabNCT00625898 · lead sponsor · 2008-04-01

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerNCT00486668 · lead sponsor · 2007-07-01

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast CancerNCT00464646 · lead sponsor · 2007-05-01

Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast CancerNCT00089323 · lead sponsor · 2007-01-01

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By SurgeryNCT00408408 · lead sponsor · 2006-11-01

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast CancerNCT00382070 · lead sponsor · 2006-08-01

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast CancerNCT00365417 · lead sponsor · 2006-08-01

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast CancerNCT00110695 · lead sponsor · 2005-04-01

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast CancerNCT00103181 · lead sponsor · 2005-03-01

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast CancerNCT00093795 · lead sponsor · 2004-10-01

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast CancerNCT00087178 · lead sponsor · 2004-05-01

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast CancerNCT00052169 · lead sponsor · 2003-01-01

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation TherapyNCT00053898 · lead sponsor · 2003-01-01

A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast CancerNCT00378313 · lead sponsor · 2001-11-01

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of TamoxifenNCT00016432 · lead sponsor · 2001-05-01

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast CancerNCT00009945 · lead sponsor · 2001-01-01

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2NCT00004067 · lead sponsor · 2000-02-01

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenNCT00003906 · lead sponsor · 1999-05-01

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast CancerNCT00003830 · lead sponsor · 1999-05-01

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph NodesNCT00003782 · lead sponsor · 1999-03-01

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast CancerNCT00003352 · lead sponsor · 1998-06-01

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast CancerNCT00002967 · lead sponsor · 1997-05-01

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically RemovedNCT00002707 · lead sponsor · 1995-12-01

Tamoxifen StudyNCT00000529 · lead sponsor · 1992-05-01

Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45NCT00914043 · lead sponsor

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)NCT06401421 · collaborator · 2024-06-07

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · collaborator · 2022-12-12

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · collaborator · 2020-12-04

ACTIVE_NOT_RECRUITING

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerNCT04024800 · collaborator · 2019-05-03

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · collaborator · 2017-07-12

ACTIVE_NOT_RECRUITING

PALbociclib CoLlaborative Adjuvant StudyNCT02513394 · collaborator · 2015-08-01

ACTIVE_NOT_RECRUITING

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerNCT02032277 · collaborator · 2014-04-02

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryNCT01864746 · collaborator · 2013-10-30

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)NCT01772472 · collaborator · 2013-04-03

Treatment With Pazopanib for Neoadjuvant Breast CancerNCT00849472 · collaborator · 2009-07-01

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)NCT00310180 · collaborator · 2006-04-07

ACTIVE_NOT_RECRUITING

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.NCT00127205 · collaborator · 2005-07-01

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerNCT00066690 · collaborator · 2003-12-17

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast CancerNCT00074152 · collaborator · 2002-07-01

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerNCT00028990 · collaborator · 2002-01-29

S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast CancerNCT00005983 · collaborator · 2000-06-01

Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast CancerNCT00005957 · collaborator · 2000-03-09

Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast CancerNCT00002762 · collaborator · 1996-06-01

Drugs studied in this sponsor's trials

37 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing NSABP Foundation Inc as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

cyclophosphamide18

doxorubicin11

docetaxel10

paclitaxel10

placebo6

trastuzumab6

bevacizumab5

letrozole4

cyclophosphamide RxCUI 3002 · Lead sponsor in 17 linked trial(s) · 0 currently recruiting 18 trials doxorubicin RxCUI 3639 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 11 trials docetaxel RxCUI 72962 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 10 trials paclitaxel RxCUI 56946 · Lead sponsor in 8 linked trial(s) · 0 currently recruiting 10 trials placebo RxCUI 8375 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 6 trials trastuzumab RxCUI 224905 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 6 trials bevacizumab RxCUI 253337 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 5 trials letrozole RxCUI 72965 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials tamoxifen RxCUI 10324 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials ado-trastuzumab emtansine RxCUI 1371041 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials Adriamycin RxCUI 42512 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials capecitabine RxCUI 194000 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 3 trials epirubicin RxCUI 3995 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials exemestane RxCUI 258494 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials neratinib RxCUI 1940643 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials palbociclib RxCUI 1601374 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials tamoxifen citrate RxCUI 40137 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials anastrozole RxCUI 84857 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials fluorouracil RxCUI 4492 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial clodronate disodium RxCUI 1546871 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial doxorubicin hydrochloride RxCUI 142433 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor42

collaborator18

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.